Cargando…
Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
Autores principales: | Serna, Angel, Sanchez, Angela, Lopez, Laia, Sancho, Juan-Manuel, Gonzalez Barca, Eva, Lopez-Garcia, Alberto, Cordoba, Raul, Sáez Marín, Adolfo Jesús, Jiminez Ubieto, Ana Isabel, Ferrero, Ainara, García, Tomas, Cabirta, Alba, Jimenez, M Moraima, Martin, Lucia, Julia, Marta, Bobillo, Sabela, Marin-Niebla, Ana, Bosch, Francesc, Abrisqueta, Pau |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665266/ http://dx.doi.org/10.1182/blood-2022-165996 |
Ejemplares similares
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
por: Sancho, Juan-Manuel, et al.
Publicado: (2022) -
PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma
por: Ligero, Marta, et al.
Publicado: (2023) -
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Giné, Eva, et al.
Publicado: (2022) -
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022) -
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell
lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)